Rapid COVID-19 Prognostic Blood Test for Disease Severity Using Epigenetic Immune System Biomarkers

Area of Science:

• Immunology
• Epigenetics
• Bioinformatics

Background:

• COVID-19 can lead to severe complications like Acute Respiratory Distress Syndrome (ARDS).
• Predicting disease severity is crucial for timely medical intervention and resource management.
• Current methods for assessing COVID-19 severity risk have limitations.

Purpose of the Study:

• To develop a novel whole-blood epigenetic biomarker (EpiMarker) for immune system status.
• To identify individuals with recent COVID-19 diagnosis at risk for severe symptoms, including ARDS.
• To create a diagnostic tool for predicting COVID-19 progression to critical care.

Main Methods:

• Utilized a methyl-sensitive restriction endonuclease approach to analyze DNA methylation profiles.
• Employed a machine-learning computational bioinformatics platform to identify immune system phenotype EpiMarkers.
• Developed a diagnostic network of 20-40 DNA methylation sites with high predictive power for ARDS risk.

Main Results:

• Whole-blood immune system status provides a sensitive indicator of functional pathway regulation.
• DNA methylation profiles reveal immune cell response readiness, offering insights into patient health.
• The identified EpiMarkers can predict the likelihood of COVID-19 progressing to ARDS requiring intensive care.

Conclusions:

• The novel EpiMarker technology enables early identification of patients at risk for severe COVID-19 and ARDS.
• This biomarker facilitates proactive patient triage, optimizing allocation of hospital resources and treatments.
• The EpiMarker assay has potential applications in screening critical personnel and preparing for future pandemics.